AKRO Akero Therapeutics Inc

Price (delayed)

$21.8

Market cap

$759.21M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.52

Enterprise value

$572.72M

Highlights
Akero Therapeutics's quick ratio has surged by 63% YoY and by 20% QoQ
Akero Therapeutics's EPS has increased by 27% YoY
AKRO's equity has surged by 108% year-on-year but it is down by 4.9% since the previous quarter
AKRO's net income has shrunk by 64% YoY and by 4% QoQ

Key stats

What are the main financial stats of AKRO
Market
Shares outstanding
34.83M
Market cap
$759.21M
Enterprise value
$572.72M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.08
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$82.41M
EBITDA
-$82.19M
Free cash flow
-$77.98M
Per share
EPS
-$2.52
Free cash flow per share
-$2.24
Book value per share
$7.08
Revenue per share
$0
TBVPS
$7.41
Balance sheet
Total assets
$257.62M
Total liabilities
$11.6M
Debt
$1.47M
Equity
$246.02M
Working capital
$245.64M
Liquidity
Debt to equity
0.01
Current ratio
25.23
Quick ratio
24.66
Net debt/EBITDA
2.27
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-34.9%
Return on equity
-36.8%
Return on invested capital
-120.8%
Return on capital employed
-33.3%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

AKRO stock price

How has the Akero Therapeutics stock price performed over time
Intraday
1.68%
1 week
0.14%
1 month
-11.81%
1 year
-37.91%
YTD
-15.5%
QTD
-12.13%

Financial performance

How have Akero Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$82.9M
Net income
-$82.41M
Gross margin
N/A
Net margin
N/A
AKRO's net income has shrunk by 64% YoY and by 4% QoQ
Akero Therapeutics's operating income has plunged by 58% YoY and by 3.4% from the previous quarter

Growth

What is Akero Therapeutics's growth rate over time

Valuation

What is Akero Therapeutics stock price valuation
P/E
N/A
P/B
3.08
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Akero Therapeutics's EPS has increased by 27% YoY
AKRO's equity has surged by 108% year-on-year but it is down by 4.9% since the previous quarter
The stock's P/B is 32% below its last 4 quarters average of 4.5

Efficiency

How efficient is Akero Therapeutics business performance
Akero Therapeutics's return on invested capital has increased by 24% YoY but it has decreased by 8% QoQ
Akero Therapeutics's return on equity has increased by 11% QoQ
The ROA has grown by 10% from the previous quarter

Dividends

What is AKRO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AKRO.

Financial health

How did Akero Therapeutics financials performed over time
The company's total assets has surged by 103% YoY but it fell by 6% QoQ
The current ratio has soared by 66% year-on-year and by 22% since the previous quarter
AKRO's debt is 99% smaller than its equity
AKRO's equity has surged by 108% year-on-year but it is down by 4.9% since the previous quarter
AKRO's debt is down by 3.2% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.